NanoString Technologies Announces Presentation of Three Studies on PAM50-based Breast Cancer Assay at 2012 CTRC-AACR San Antonio Breast Cancer Symposium

NanoString Technologies Announces Presentation of Three Studies on PAM50-based Breast Cancer Assay at 2012 CTRC-AACR San Antonio Breast Cancer Symposium

NanoString Technologies, Inc.Maurissa Messier, 1-760-539-7417

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic products, today announced that results from three studies of its diagnostic breast cancer assay based on the PAM50 gene expression signature will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place this week at the Henry B. Gonzalez Convention Center. The studies will be presented on Thursday, December 6 and include the second clinical validation study for prognosis in postmenopausal women with hormone-receptor positive early-stage breast cancer treated with endocrine therapy alone, and two investigator-initiated studies.

Following are details for each study and presentation session.

NanoString’s PAM50-based breast cancer assay can provide a subtype classification based on the fundamental biology of an individual’s breast tumor (referred to as intrinsic subtyping), as well as a prognostic score (referred to as the risk of recurrence, or ROR, score). The ROR score indicates the probability of cancer recurrence over 10 years in post-menopausal women with HR+ early-stage breast cancer who have been treated with endocrine therapy alone. Together with studies from the literature, the ROR score and intrinsic subtype have been shown to convey clinically relevant information about a patient’s prognosis.

NanoString has an exclusive worldwide license for the PAM50 gene signature to develop diagnostic and research products for breast cancer on its nCounter Analysis System. The clinical development program for NanoString’s PAM50-based assay is designed to support both regulatory requirements for market-specific clearance or approval and its incorporation into breast cancer treatment guidelines worldwide. In September 2012, NanoString obtained the CE Mark for its PAM50-based assay, clearing the company to sell it in the European Union and other countries recognizing the CE Mark. The PAM50 gene signature has not been cleared for marketing in the United States, and the nCounterAnalysis System is currently labeled for “Research Use Only”.

More information is available at .

NanoString Technologies is a privately held provider of life science tools for translational research and developer of molecular diagnostic products. The company’s nCounter Analysis System delivers highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing its technology for use in molecular diagnostics. The company’s first molecular diagnostic product is a breast cancer assay based on the PAM50 gene expression signature.

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.